534-51-0

Basic information

• Product Name: 3,5-DIIODO-DL-THYRONINE
• Synonyms: 3,5-DIIODO-DL-THYRONINE;2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodo-phenyl]-propanoic acid;2-Amino-3-[4-(p-hydroxyphenoxy)-3,5-diiodophenyl]propionic acid;2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodo-phenyl]propionic acid;2-azanyl-3-[4-(4-hydroxyphenoxy)-3,5-diiodo-phenyl]propanoic acid;DL-3,5-Diiodothyronine;DIIODO-L-THYRONINE, 3,5-(RG)(REQUEST QUOTE);DIIODO-L-THYRONINE, 3,5-(P)
• CAS NO: 534-51-0
• Molecular Formula: C₁₅H₁₃I₂NO₄
• Molecular Weight: 525.08
• Mol File: 534-51-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 250-252 °C
• Boiling Point: 559.4°Cat760mmHg
• Flash Point: 292.1°C
• Appearance: /
• Density: 2.095g/cm³
• PKA: 2.15±0.30(Predicted)
• CAS DataBase Reference: 3,5-DIIODO-DL-THYRONINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIIODO-DL-THYRONINE(534-51-0)
• EPA Substance Registry System: 3,5-DIIODO-DL-THYRONINE(534-51-0)

Safety Data

• Hazardous Substances Data: 534-51-0(Hazardous Substances Data)

Usage

General Description

3,5-DIIODO-DL-THYRONINE is a synthetic compound with chemical properties similar to the thyroid hormone, triiodothyronine (T3). It is also known as 3,5-diiodo-L-thyronine and is structurally similar to T3 but has different biological effects. 3,5-DIIODO-DL-THYRONINE has been studied for its potential role in regulating energy metabolism, improving lipid metabolism, and reducing body weight. It has been investigated as a potential treatment for obesity, metabolic syndrome, and related conditions. However, further research is needed to fully understand its effects and potential therapeutic applications.

Upstream product

• 51-48-9 L-thyroxine 
• 21959-36-4 N-acetyl-3,5-diiodo-L-tyrosine ethyl ester 
• 1027-28-7 N-acetyl-3,5-diiodo-L-tyrosine 
• 300-39-0 3,5-diiodo-l-tyrosine 
• 83249-56-3 N-acetyl-O-(4-methoxyphenyl)-3,5-diiodo-L-tyrosine ethyl ester 
• 19231-06-2 4,4'-dimethoxy-diphenyliodonium bromide 
• 94345-95-6 2-amino-3-(3,5-diiodo-4-(4-methoxyphenoxy)phenyl)propanoic acid 
• 49553-16-4 {Cu(HOC₆H₂I₂CH₂CH(NH₂)COO)2} 
• 178877-78-6 C₂₀H₂₁I₂NO₆ 
• 1431868-05-1 C₂₁H₂₃I₂NO₆ 
• 1016161-91-3 C₃₀H₄₃I₂NO₆Si 
• 128781-80-6 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3,5-diiodophenyl)propanoate 
• 4326-36-7 (S)-N-(tert-butoxycarbonyl)tyrosine methyl ester 
• 1080-06-4 L-Tyr-OMe 

Downstream Products

• 94298-44-9 N-formyl-3,5-diiodo-DL-thyronine 
• 4299-88-1 3',5'-dibromo-3,5-diiodo-thyronine 
• 300-30-1 thyroxine 
• 1034-10-2 DL-thyronine 
• 16170-92-6 3-iodo-DL-thyronine 
• 3130-96-9 3,5,3'-Trijodothyronin (T₃) 
• 111149-73-6 3,5-diiodo-thyronine methyl ester; hydrochloride 
• 51-48-9 L-thyroxine 
• 1041-01-6 3,5-diiodo-L-thyronine 
• 5563-89-3 D-Diiodothyronine 
• 51-49-0 dextrothyroxine 
• 94298-44-9 N-formyl-3,5-diiodo-L-thyronine 
• 120408-14-2 N-formyl-3,5-diiodo-D-thyronine 
• 203585-45-9 3,5-diiodo-L-thyronine methyl ester 

Relevant articles and documents

Reductive dehalogenation and dehalogenative sulfonation of phenols and heteroaromatics with sodium sulfite in an aqueous medium

Prototropic tautomerism was used as a tool for the reductive dehalogenation of (hetero)aryl bromides and iodides, or dehalogenative sulfonation of (hetero)aryl chlorides and fluorides, using sodium sulfite as the sole reagent in an aqueous medium. This protocol does not require a metal or phase transfer catalyst and avoids using organic solvent as the reaction medium. This method is especially suitable for substrates that readily tautomerize (such as 2-or 4-halogenated aminophenols and 4-halogenated resorcinols), for which dehalogenation or sulfonation proceeds under mild reaction conditions (≤60 °C). As sodium sulfite is an inexpensive, safe, and environmentally less hazardous reagent, this method has at least three potential applications: (i) in the deprotection of halogens as protecting groups, using sodium sulfite as a reducing agent; (ii) in the sulfonation of aromatic halides under mild reaction conditions avoiding hazardous and corrosive reagents/solvents; and (iii) in the transformation of toxic halogenated aromatics into less harmful compounds.

Improved method for synthesizing L-thyroxine sodium

The invention relates to an improved method for synthesizing L-thyroxine sodium. The improved method includes the steps that 3,5-diiodomethane-L-tyrosine is used as a raw material, and then subjectedto a copper complex reaction, a coupling reaction, an acid hydrolysis reaction, an iodine generation reaction and a salt forming reaction to obtained the L-thyroxine sodium. According to the improvedmethod for synthesizing the L-thyroxine sodium, the yield of the L-thyroxine sodium can be improved, the product cost is lowered, and industrialization is convenient.

PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE

The present invention relates to a pharmaceutical composition comprising, as active substance, at least one hormone chosen among 3,5-diiodothyronine (3,5-T2), 3′,3-diiodothyronine (3′,3-T2), 3′,5-diiodothyronine (3′,5-T2), 3′-iodothyronine (3′-T), 3-iodothyronine (3-T) or 5-iodothyronine (5-T), in association with a pharmaceutically acceptable vehicle.